Trial · NCT05831969
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
NCT05831969, Phase 2, Unknown, Shenyang Tenth People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC. Trials, record NCT05831969. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05831969
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
- NCT number
- NCT05831969
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 23 participants, estimated
- Lead sponsor
- Shenyang Tenth People's Hospital
- Conditions
- Advanced HCC
- Interventions
- Lenalidomide
- First posted
- 2023-04-26
- Last updated
- 2023-04-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR | up to approximately 24 months | Defines the proportion of patients whose tumor volume shrinks to a prespecified value and is maintained for a minimum period of time. The RECIST 1.1 standard was adopted, including complete remission of CR and partial remission of PR. |
| Secondary | PFS | Randomization to the first occurrence of disease progression or death from any cause up to the clinical cut off date of June 5,2024 | PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm). |
| Secondary | OS | up to approximately 24 months | Time from enrollment to death (for any reason); |
| Secondary | DOR | up to approximately 18 months | Time from the first CR or PR to disease progression after enrollment |
| Secondary | Percentage of Participants With Adverse Events | Up to end of study (up to approximately 24 months | An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05831969
GET https://conductscience.org/api/trials/v1/NCT05831969/registered